Search
Now showing items 71-80 of 131
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
(2021-06)
This is the accepted manuscript of an article published online:
1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908
Highly effective disease-modifying treatment as initial MS therapy.
(2021-06-01)
PURPOSE OF REVIEW: Using highly effective (HE) compounds right from the beginning of disease-modifying immunotherapy (DMT) in people with multiple sclerosis (pwMS) has gained popularity among clinicians and pwMS alike. We ...
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
(2020-12)
Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
(2020-11-12)
OBJECTIVE: To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis (MS). METHODS: We ...